CompletedPhase 2NCT03230318
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Studying Carcinoma of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Basilea Pharmaceutica
- Principal Investigator
- Manuel Häckl, MDBasilea Pharmaceutica International Ltd, Allschwil
- Intervention
- derazantinib(drug)
- Enrollment
- 148 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (30)
- Mayo Clinic, Phoenix, Arizona, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, United States
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- The University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- University of Washington Medical Center, Seattle, Washington, United States
- Hôpital Erasme, Brussels, Belgium
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Antwerp University Hospital, Edegem, Belgium
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03230318 on ClinicalTrials.govOther trials for Carcinoma of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07437859Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentPeking Union Medical College Hospital
- RECRUITINGPHASE1NCT07106827A Study of GV20-0251 in Advanced or Refractory Solid TumorsWest China Hospital
- RECRUITINGNCT07466602cfDNA Methylation for Liver Cancer Recurrence DetectionWuhan Ammunition Life-tech Co., Ltd
- RECRUITINGPHASE2NCT07105748HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)Fudan University
- RECRUITINGPHASE2NCT06766643Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT06849180Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal DataZhongda Hospital
- RECRUITINGNANCT06905015Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver ResectionWarangkana Lapisatepun
- RECRUITINGNCT06486454Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)HistoSonics, Inc.
See all trials for Carcinoma of liver and intrahepatic biliary tract →